Jeff Eiseman
Long only, deep value, special situations

PharmAthene Is A Bargain: Significance Of Recent Legal, Pipeline, And Merger Developments

Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

PharmAthene (NYSEMKT:PIP) is poised to jump. Three recent developments have affected its stock price:

  • the flu product of its prospective merger partner (Theraclone Sciences) failed to reach its clinical trial's primary endpoint, after which the Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) declined funding;
  • PharmAthene terminated its merger with Theraclone; and
  • the FDA placed a clinical hold on SparVax, PharmAthene's anthrax product.

There has also been a lack of news about the seven-year legal battle with SIGA Technologies (NASDAQ:...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details